Comparison of Patient Impact and Clinical Characteristics Between Urgency and Passive Fecal Incontinence Phenotypes.


Journal

Female pelvic medicine & reconstructive surgery
ISSN: 2154-4212
Titre abrégé: Female Pelvic Med Reconstr Surg
Pays: United States
ID NLM: 101528690

Informations de publication

Date de publication:
09 2020
Historique:
pubmed: 7 7 2018
medline: 2 10 2021
entrez: 7 7 2018
Statut: ppublish

Résumé

To determine if categorizing fecal incontinence (FI) as urgency or passive FI is clinically meaningful, we compared clinical severity, quality of life, physical examination findings, and functional and anatomic deficits between women with urgency and passive FI. This study is a prospective cross-sectional study of women with at least monthly FI. All women completed the St Mark's Vaizey and the Fecal Incontinence Quality of Life questionnaires and underwent anorectal manometry and endoanal ultrasound. We compared women with urgency FI to women with passive FI. Forty-six women were enrolled, 21 (46%) with urgency FI and 25 (54%) with passive FI. Clinical severity by Vaizey score did not differ between groups (urgency 11.7 ± 1.6 vs passive 11.0 ± 1.0, P = 0.51). Women with urgency FI had worse median (range) lifestyle and coping scores than passive FI (Fecal Incontinence Quality of Life: lifestyle domain 2.5 [1, 4] vs 3.8 [1, 4], P = 0.04; coping domain 1.7 [1, 3] vs 2.4 [0.9, 4], P < 0.01). Women with urgency FI had higher anal resting and squeeze pressure than passive FI (60 ± 4 mm Hg vs 49 ± 3 mm Hg, P = 0.03; 78 [48, 150] mm Hg vs 60 [40, 103], P = 0.05). Internal anal sphincter defects were more common in women with passive FI (41.7% vs 30.0%, P = 0.53) and external anal sphincter defects more common in women with urgency FI (25% vs 16.7%, P = 0.71), but this did not reach statistical significance. We identified functional and anatomic differences between women with urgency FI and passive FI. Pheonotyping women with FI into these subtypes is clinically meaningful.

Identifiants

pubmed: 29979355
doi: 10.1097/SPV.0000000000000603
pii: 01436319-202009000-00009
pmc: PMC8451229
mid: NIHMS1739623
doi:

Banques de données

ClinicalTrials.gov
['NCT02772874']

Types de publication

Comparative Study Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

570-574

Subventions

Organisme : NIA NIH HHS
ID : L30 AG060604
Pays : United States
Organisme : NIA NIH HHS
ID : R03 AG053277
Pays : United States

Références

Gut. 1999 Jan;44(1):77-80
pubmed: 9862829
Aliment Pharmacol Ther. 2004 Aug 1;20(3):355-64
pubmed: 15274673
Am J Gastroenterol. 1999 Mar;94(3):773-83
pubmed: 10086665
Colorectal Dis. 2012 Sep;14(9):1101-5
pubmed: 22145761
Dis Colon Rectum. 2005 Jan;48(1):134-40
pubmed: 15690670
Br J Surg. 1989 Sep;76(9):973-5
pubmed: 2679966
Neurogastroenterol Motil. 2015 Oct;27(10):1504-8
pubmed: 26227262
Am J Gastroenterol. 2007 Feb;102(2):351-61
pubmed: 17100975
Nurs Res. 1989 Jul-Aug;38(4):196-9
pubmed: 2748352
Gastroenterol Clin North Am. 1996 Mar;25(1):163-82
pubmed: 8682571
Gut. 2005 Apr;54(4):546-55
pubmed: 15753542
Int J Colorectal Dis. 1995;10(3):152-5
pubmed: 7561433
Int Urogynecol J. 2014 Jul;25(7):927-33
pubmed: 24562788
Br J Surg. 2010 Jul;97(7):1096-102
pubmed: 20632278
Int Urogynecol J. 2013 Mar;24(3):469-78
pubmed: 22806487
Gastroenterology. 2006 Apr;130(5):1480-91
pubmed: 16678561
Cochrane Database Syst Rev. 2012 Jul 11;(7):CD002111
pubmed: 22786479
Am J Gastroenterol. 2004 Aug;99(8):1585-604
pubmed: 15307881
J Korean Surg Soc. 2011 Nov;81(5):326-31
pubmed: 22148125
Clin Gastroenterol Hepatol. 2015 Jun;13(6):1143-50.e1
pubmed: 25616028
Lancet. 2015 Oct 24;386(10004):1640-8
pubmed: 26293315
Gastroenterology. 2004 Jan;126(1 Suppl 1):S14-22
pubmed: 14978634
Br J Surg. 1999 Sep;86(9):1159-63
pubmed: 10504370
Br J Surg. 1995 Sep;82(9):1179-82
pubmed: 7551990
Dis Colon Rectum. 2000 Jan;43(1):9-16; discussion 16-7
pubmed: 10813117

Auteurs

Avita K Pahwa (AK)

From the Department of Obstetrics and Gynecology, University of Southern California, Keck School of Medicine, Los Angeles, CA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH